TipRanks identified the corporate insiders with the best-performing track records and the stocks they are buying. » Read More
Judge Edgardo Ramos in Manhattan dismissed Express Scripts' claim that Anthem breached an implied covenant of good faith and fair dealing. » Read More
John Rountree, partner at Novasecta, discusses how the pharmaceutical industry is reacting to U.S. President Donald Trump's delayed health care bill. » Read More
The best-performing large-cap ETF is enjoying an incredible comeback in 2017.
China's Shanghai Fosun Pharmaceutical is planning a bid for German generic drugmaker Stada.
Promising new research suggests that marijuana could be used to treat Alzheimer's, but there's a major roadblock: the federal government.
Biotech stocks might be in a slump, but there's an upside, one analyst says.
Michael Yee, RBC Capital Markets biotech analyst, weighs in on the biotech sector amid President Trump's drug pricing concerns and GOP healthcare proposal.
EpiPen's seller Mylan came under fire last summer for having increased the price of the auto-injector more than 500 percent.
Ava is an ovulation tracking bracelet that is worn at night when the woman is sleeping to track her most fertile days.
Ava is an ovulation tracking bracelet worn at night when the woman is sleeping to track her most fertile days.
South Korea's Samsung Bioepis has won a high-stakes court case against U.S. drug firm AbbVie.
The HPV vaccine is increasingly becoming the primary test for reducing cervical cancer deaths, STAT News reports.
Mylan was criticized last year after hiking EpiPen prices to $600, but has seen its stock surge after Donald Trump's election.
CNBC's Jim Cramer weighs in on Mylan and CEO Heather Bresch.
CNBC's Brian Sullivan asks Mylan CEO Heather Bresch about the company's outperformance relative to its peers.
Mylan CEO Heather Bresch discusses the company's progress from its EpiPen firestorm.
Plurimi Investment Managers CIO Patrick Armstrong weighs in on his investment strategy, adding that almost everything has been overpriced in the last two months.
The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia, a rare and deadly blood cancer.
Leerink says Sarepta Therapeutics will generate $89 million in 2017 sales vs. management's guidance of more than $80 million.
Amicus Therapeutics CEO Crowley is optimistic about Trump's plans to work with the pharma industry, proposing change for good.
The stock slid sharply in morning trading before rebounding to climb about 1 percent higher Wednesday.
Shares of EpiPen maker Mylan climbed on the heels of the company reporting fourth-quarter earnings that topped expectations.
Get the best of CNBC in your inbox